Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
White Heart Failure Hypertension 	Oral Hypoglycemic Agents Olmesartan

White Heart Failure Hypertension Oral Hypoglycemic Agents Olmesartan

  • High Light

    Hypertension Vardenafil Powder


    Heart Failure Vardenafil Powder


    Ogilvy sha Tanzania Powder

  • Product Name
  • Purity
  • Place Of Origin
  • Shelf Life
    2 Years
  • Storage
    Cool Dry Place
  • Brand Name
    Kan Ying
  • Melting Point
  • Color
    White Powder
  • Place of Origin
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
  • Price
    To discuss
  • Packaging Details
  • Delivery Time
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability

White Heart Failure Hypertension Oral Hypoglycemic Agents Olmesartan

White Heart Failure Hypertension Oral Hypoglycemic Agents Olmesartan


1. Product title:Olmesartan

2. Product parameter table:

Product Name Olmesartan Specification 99%
Appearance White powder Main Effect Hypertension
Brand Name Kan Ying Store-method Cool Dry Place
Shelf Life 2 Years When
Properly Stored
From India

3. Product Description:

Under the catalysis of angiotensin converting enzyme (ACE, kinase Ⅱ), angiotensin I(AT L) is transformed into angiotensin IL (AT R). Angiotensin Ⅱ is a major pressure-boosting factor in the renin-angiotensin system. Its functions include constricting blood vessels, promoting the synthesis and release of aldosterone, stimulating the heart, and promoting sodium reabsorption by the kidneys. Omesartan ester is a precursor drug that is hydrolyzed to Omesartan by gastrointestinal absorption. Omesartan is a selective angiotensin-Ⅱ type 1 receptor (AT1) antagonist that blocks the vasoconstrictive effect of the angiotensin-receptor by selectively blocking the binding of angiotensin-receptor to the vascular smooth muscle AT1 receptor, so its action is independent of the ATL synthesis pathway. Omesartan's affinity for AT1 is more than 12,500 times stronger than its affinity for AT2. Blocking the renin-angiotensin system (RAS) with ACE inhibitors is a mechanism of many drugs for the treatment of hypertension, but ACE inhibitors also inhibit bradykinin degradation, whereas olmesartan does not inhibit ACE, so it does not affect bradykinin. Whether this difference is clinically relevant is unclear. Blocking the angiotensin Ⅱ receptor inhibits the negative feedback regulation mechanism of angiotensin receptor on renin secretion. However, the resulting increase in plasma renin activity and circulating angiotensin Ⅱ concentration did not affect the hypotensive effect of olmesartan.

4. Adverse reactions:

The safety of olmesartan estate was evaluated in controlled clinical trials of up to 3,275 patients, with approximately 900 patients receiving treatment for at least six months and more than 525 patients receiving treatment for one year. The results showed that olmesartan was well tolerated and had a similar adverse event rate as placebo. Adverse events were usually mild and transient and were not related to dose, age, or ethnicity. In placebo-controlled clinical trials, the only adverse event that was greater than 1% in patients receiving olmesartan ester and higher than in the placebo group was dizziness (3%vs S1%); The incidence was similar to placebo, with adverse events greater than 1% : back pain, bronchitis, elevated creatine phosphokinase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, pharyngitis, rhinitis, and sinusitis. The incidence of cough was similar in the placebo group (0.7%) and olmesartan dipivoxil group (0.9%). Similar to the placebo group, the incidence of less than 1% or more than 0.5% of adverse events are: chest pain, fatigue, pain, peripheral edema, dizziness, abdominal pain, dyspepsia, gastroenteritis, nausea, tachycardia, hypercholesterolemia, hyperlipidemia, high uric acid hematic disease, joint pain, arthritis, muscle pain, bone pain, rashes and facial edema, etc. It is not clear whether the above adverse events are related to this product. Laboratory results: Changes in clinically significant laboratory parameters were associated with lower levels of olmesartan ester in controlled clinical trials. HEMOGLOBIN AND HEMOGLOBIN VOLUMES: Slight decreases in HEMOGLOBIN and HEMOGLOBIN were observed occasionally (by about 0.3g/dL and 0.3 volume percentage, respectively). Liver function test: occasional increase in liver enzymes and/or blood bilirubin, but will be normal by itself. Past market experience: rhabdomyolysis caused by angiotensin Ⅱ receptor antagonists has been rarely reported.

5. Drug interaction:

Omesartan ester is not metabolized by the liver cytochrome P450 system and has no effect on P450 enzyme. Thus, there are no drug interactions associated with inhibition, induction, or metabolism of these enzymes. The combination of digoxin or warfarin in healthy subjects did not show significant drug interactions, nor did the combination of an antacid [Al(OH)3/Mg(OH)2] significantly alter the bioavailability of olmesartan ester.

6. Antihypertensive effects:

Omesartan has excellent antihypertensive effect. Seven placebo-controlled clinical studies showed a potent antihypertensive effect of olmesattan, with daily doses of 5 mg, 20 mg and 40 mg reducing sitting systolic blood pressure by 12.4 mmHg, 15.1 mmHg and 17.6 mmHg respectively. The antihypertensive effect of olmesattan diastolic diastolic blood pressure decreased by 9.8 mmHg, 12.2 mmHg and 13.1 mmHg in different sex and age (lt; 65 years or older) did not differ significantly. The recommended starting dose for the U.S. market is 20 mg/ day, with additional doses up to 40 mg/ day if necessary. The antihypertensive effect of olmesartan dipionate at 20 mg qd was observed. On 24-hour ambulatory blood pressure monitoring, this dose reduced mean systolic blood pressure by 15.2 mmHg and mean diastolic blood pressure by 11.2 mmHg, which was the same as olmesartan dipionate at 10 mg bid and was significantly better than placebo. In addition, the blood pressure decreased significantly and to similar degree at each observation time point. Clinical observation fully confirms that oral administration of olmesartan dipionate once a day can control blood pressure for 24 hours.


7. Pictures of the product:

White Heart Failure Hypertension 	Oral Hypoglycemic Agents Olmesartan 0White Heart Failure Hypertension 	Oral Hypoglycemic Agents Olmesartan 1